|
1
|
Omata M, Cheng AL, Kokudo N, Kudo M, Lee
JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, et al:
Asia-Pacific clinical practice guidelines on the management of
hepatocellular carcinoma: A 2017 update. Hepatol Int. 11:317–370.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
European Association for the Study of the
Liver, Electronic address: easloffice@easloffice.eu; European
Association for the Study of the Liver. EASL Clinical Practice
Guidelines: Management of hepatocellular carcinoma. J Hepatol.
69:182–236. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Marrero JA, Kulik LM, Sirlin CB, Zhu AX,
Finn RS, Abecassis MM, Roberts LR and Heimbach JK: Diagnosis,
staging, and management of hepatocellular carcinoma: 2018 practice
guidance by the American association for the study of liver
diseases. Hepatology. 68:723–750. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kelley RK, Sangro B, Harris W, Ikeda M,
Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, et al: Safety,
efficacy, and pharmacodynamics of tremelimumab plus durvalumab for
patients with unresectable hepatocellular carcinoma: Randomized
expansion of a phase I/II study. J Clin Oncol. 39:2991–3001.
2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Okuda K, Obata H, Nakajima Y, Ohtsuki T,
Okazaki N and Ohnishi K: Prognosis of primary hepatocellular
carcinoma. Hepatology. 4 (1 Suppl):3S–6S. 1984.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hanazaki K, Kajikawa S, Shimozawa N,
Shimada K, Hiraguri M, Koide N, Adachi W and Amano J: Hepatic
resection for hepatocellular carcinoma in the elderly. J Am Coll
Surg. 192:38–46. 2001.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sato M, Tateishi R, Yasunaga H, Horiguchi
H, Yoshida H, Matsuda S and Koike K: Mortality and morbidity of
hepatectomy, radiofrequency ablation, and embolization for
hepatocellular carcinoma: A national survey of 54,145 patients. J
Gastroenterol. 47:1125–1133. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Marta GN, da Fonseca LG, Braghiroli MI,
Moura F, Hoff PM and Sabbaga J: Efficacy and safety of sorafenib in
elderly patients with advanced hepatocellular carcinoma. Clinics
(Sao Paulo). 76(e2498)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hatanaka T, Kakizaki S, Hiraoka A, Tada T,
Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi
E, et al: Comparative analysis of the therapeutic outcomes of
atezolizumab plus bevacizumab and lenvatinib for hepatocellular
carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res: Nov 20, 2023 (Epub ahead of print).
|
|
11
|
Ishikawa T, Yamazaki S, Sato R, Jimbo R,
Kobayashi Y, Sato T, Iwanaga A, Sano T, Yokoyama J and Honma T:
Efficacy of adding locoregional therapy in non-complete remission
hepatocellular carcinoma treated with atezolizumab plus
bevacizumab: A preliminary study. Anticancer Res. 44:361–368.
2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gatson NTN, Makary M, Bross SP, Vadakara
J, Maiers T, Mongelluzzo GJ, Leese EN, Brimley C, Fonkem E,
Mahadevan A, et al: Case series review of neuroradiologic changes
associated with immune checkpoint inhibitor therapy. Neurooncol
Pract. 8:247–258. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y
and Makuuchi M: Staging of hepatocellular carcinoma: Assessment of
the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772
patients in Japan. Ann Surg. 245:909–922. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hosoda K, Toshima T, Takahashi J, Yonemura
Y, Hisamatsu Y, Hirose K, Masuda T, Motomura Y, Abe T, Ando Y, et
al: Successful multidisciplinary treatment with complete response
to atezolizumab plus bevacizumab in a 90-year-old patient with
hepatocellular carcinoma recurrence. Int Cancer Conf J. 12:274–278.
2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mollica V, Rizzo A, Marchetti A, Tateo V,
Tassinari E, Rosellini M, Massafra R, Santoni M and Massari F: The
impact of ECOG performance status on efficacy of immunotherapy and
immune-based combinations in cancer patients: The MOUSEION-06
study. Clin Exp Med. 23:5039–5049. 2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Shiratori Y, Shiina S, Zhang PY, Ohno E,
Okudaira T, Payawal DA, Ono-Nita SK, Imamura M, Kato N and Omata M:
Does dual infection by hepatitis B and C viruses play an important
role in the pathogenesis of hepatocellular carcinoma in Japan?
Cancer. 80:2060–2067. 1997.PubMed/NCBI
|
|
19
|
Chiu CM, Yeh SH, Chen PJ, Kuo TJ, Chang
CJ, Chen PJ, Yang WJ and Chen DS: Hepatitis B virus X protein
enhances androgen receptor-responsive gene expression depending on
androgen level. Proc Natl Acad Sci USA. 104:2571–2578.
2007.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kanda T, Steele R, Ray R and Ray RB:
Hepatitis C virus core protein augments androgen receptor-mediated
signaling. J Virol. 82:11066–11072. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Santoni M, Rizzo A, Mollica V, Matrana MR,
Rosellini M, Faloppi L, Marchetti A, Battelli N and Massari F: The
impact of gender on The efficacy of immune checkpoint inhibitors in
cancer patients: The MOUSEION-01 study. Crit Rev Oncol Hematol.
170(103596)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Xie E, Yeo YH, Scheiner B, Zhang Y,
Hiraoka A, Tantai X, Fessas P, de Castro T, D'Alessio A, Fulgenzi
CAM, et al: Immune checkpoint inhibitors for child-pugh class B
advanced hepatocellular carcinoma: A systematic review and
meta-analysis. JAMA Oncol. 9:1423–1431. 2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Tanaka T, Hiraoka A, Tada T, Hirooka M,
Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E,
Fukunishi S, et al: Therapeutic efficacy of atezolizumab plus
bevacizumab treatment for unresectable hepatocellular carcinoma in
patients with Child-Pugh class A or B liver function in real-world
clinical practice. Hepatol Res. 52:773–783. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ramaswamy A, Kulkarni A, John G, Rauthan
A, Patil S, Duseja A, Talwar V, Rajappa SJ, Ghadyalpatil N,
Wadhawan M, et al: Survival of trial-like and non-trial-like
patients with immunotherapy in advanced hepatocellular carcinoma in
real world: A collaborative multicenter indian study (IMHEP). JCO
Glob Oncol. 9(e2300215)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Barakat RK, Singh N, Lal R, Verani RR,
Finkel KW and Foringer JR: Interstitial nephritis secondary to
bevacizumab treatment in metastatic leiomyosarcoma. Ann
Pharmacother. 41:707–710. 2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Xipell M, Victoria I, Hoffmann V,
Villarreal J, García-Herrera A, Reig O, Rodas L, Blasco M, Poch E,
Mellado B and Quintana LF: Acute tubulointerstitial nephritis
associated with atezolizumab, an anti-programmed death-ligand 1
(pd-l1) antibody therapy. Oncoimmunology.
7(e1445952)2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Jagieła J, Bartnicki P and Rysz J:
Nephrotoxicity as a complication of chemotherapy and immunotherapy
in the treatment of colorectal cancer, melanoma and non-small cell
lung cancer. Int J Mol Sci. 22(4618)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Gao X, Zhao R, Ma H and Zuo S: Efficacy
and safety of atezolizumab plus bevacizumab treatment for advanced
hepatocellular carcinoma in the real world: A single-arm
meta-analysis. BMC Cancer. 23(635)2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kulkarni AV, Tevethia H, Kumar K,
Premkumar M, Muttaiah MD, Hiraoka A, Hatanaka T, Tada T, Kumada T,
Kakizaki S, et al: Effectiveness and safety of
atezolizumab-bevacizumab in patients with unresectable
hepatocellular carcinoma: A systematic review and meta-analysis.
EClinicalMedicine. 63(102179)2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Rizzo A, Ricci AD and Brandi G: Systemic
adjuvant treatment in hepatocellular carcinoma: Tempted to do
something rather than nothing. Future Oncol. 16:2587–2589.
2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M,
Lee HC, Yopp AC, Zhou J, Wang L, Wen X, et al: Atezolizumab plus
bevacizumab versus active surveillance in patients with resected or
ablated high-risk hepatocellular carcinoma (IMbrave050): A
randomised, open-label, multicentre, phase 3 trial. Lancet.
402:1835–1847. 2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Rizzo A, Ricci AD and Brandi G:
Trans-Arterial chemoembolization plus systemic treatments for
hepatocellular carcinoma: An update. J Pers Med.
12(1788)2022.PubMed/NCBI View Article : Google Scholar
|
